NCGC607

CAS No. 1462267-07-7

NCGC607( —— )

Catalog No. M23622 CAS No. 1462267-07-7

NCGC607 is a a noninhibitory chaperone of glucocerebrosidase (GCase).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 102 In Stock
2MG 39 In Stock
5MG 79 In Stock
10MG 126 In Stock
25MG 214 In Stock
50MG 309 In Stock
100MG 440 In Stock
200MG 617 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    NCGC607
  • Note
    Research use only, not for human use.
  • Brief Description
    NCGC607 is a a noninhibitory chaperone of glucocerebrosidase (GCase).
  • Description
    NCGC607 is a a noninhibitory chaperone of glucocerebrosidase (GCase).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1462267-07-7
  • Formula Weight
    543.36
  • Molecular Formula
    C24H22IN3O4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 62.5 mg/mL (115.03 mM)
  • SMILES
    CN(C1=CC=CC=C1)C(=O)CNC(=O)C2=CC=CC=C2OCC(=O)NC3=CC=C(C=C3)I
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Aflaki E , Borger D K , Moaven N , et al. A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism[J]. Journal of Neuroscience the Official Journal of the Society for Neuroscience, 2016, 36(28):7441.
molnova catalog
related products
  • Neuronostatin-13 (hu...

    Neuronostatin-13 (human, canine, porcine)

  • Biatractylolide

    Biatractylolide has a neuroprotective effect on glutamate-induced injury in PC12 and SH-SY5Y cells through a mechanism of the PI3K-Akt-GSK3β-dependent pathways.

  • Picrasidine I

    Picrasidine I has antiosteoclastogenic effect by inhibiting inflammation induced activation of MAPKs, ROS generation followed by suppressing the gene expression of c-Fos and NFATc1 in osteoclast precursors.